Webinars

View this webinar for an in-depth exploration of today's complex global market landscape. This panel will address the challenges of launching new therapies in multiple countries, focusing on early decision points for risk mitigation and maximizing supply chain resiliency. Discover how Cencora's global capabilities and flexible solutions can strengthen supply chain resilience amidst evolving challenges.
 

Moderator: Sandra Anderson, Senior Vice President Commercialization, Cencora

Panelists:

• Glenn Pauly, Chief Commercial Officer, Alzheon
• Graham Goodrich, Chief Commercial Officer, Apnimed
• Leigh Shultz, PhD, Associate Vice President & International Head of Trade Channel Strategy & Enablement, Merck & Co.
• Kevin McDermott, Vice President International Commercialization, Cencora
• Tom Doyle, Head of U.S. Commercial Solutions, Cencora

BIO's new and improved partnering system — BIO Partnering™ — will open for the 2025 BIO International convention in early April. Join BIO's VP of Partnering, Mackensie Vernetti, for a webinar showcasing the new platform, complete with an in-depth live demo, as well as partnering tips and best practices. This webinar will provide the tools and guidance to maximize your experience at the event.

Key Takeaways:

• In-Depth Look at the Partnering System: Learn about features that streamline partnering discovery and make easy work of meeting management.
• What's New: See the newest system enhancements in action.
• Best Practices: Advice on how to search and find partners, send quality meeting requests and triage your messages.
• Quick Tips: Discover shortcuts and helpful tools to save you time.

Learn more about the BIO International Convention at

https://convention.bio.org/

The BIO International Convention is the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with 20,000 industry leaders from across the globe.

In a time of remarkable discovery and progress, the biotechnology industry stands at the forefront of a revolution changing how we live, heal, and care.  View this webinar for a tour of the program's featured sessions, super sessions, and notable expert speakers, across the more than 140 sessions planned for BIO 2025 in Boston, June 16-19.   Also, this webinar will be your first look at several new program session types and event surprises in progress, including a BIO Storytelling Stage, new evening reception venues, and an expanded main stage experience that will debut this year.  The webinar includes advice on planning your calendar to maximize the value of attending.

Join Sydney Williams, BIO Senior Manager, Exhibit Sales & Systems, for a webinar to walk exhibitors through the tools needed to plan for the 2025 BIO International Convention. 

This webinar gives our exhibitors the resources to have an impactful presence in Boston. 

The following topics are discussed: 

• Exhibitor resource center
• Exhibitor tools and resources
• Tips to maximize your event experience in Boston

More than $4B of deals between biopharma companies and AI specialists were announced last year. Similar to the massive quality leap from GPT-2 to GPT-4 and the record-breaking consumer adoption rates of AI tools, that same exponential progress and uptake is coming to biotech AI. 2024 may bring the first one-trillion-parameter protein language model. Companies are already using AI to program, as opposed to discover, antibodies. This level of opportunity and change brings with it urgency—— companies need to rethink from the ground up how their R&D should work to compete in a new era defined by the intersection of biology, data, and AI.

In this webinar, learn how companies are updating their approach to R&D, with a focus on:

1. AI-Ready Data: Improving generation of high-quality biomedical data to support AI model building and model tuning
2. AI-Enabled Scientists: Integrating the right models directly into scientists’ workflows for everyday use
3. Scalability: Making performance, speed, privacy, and cost tradeoffs for deployment of AI, and connecting the wet and dry labs

BIO One-on-One Partnering™ is back at the San Francisco Marriott Marquis for JPM Week 2025 and with 70% more meeting space! View this webinar to hear about how BIO’s partnering system can help you source new partnerships and manage your meetings for JPM Week. Learn about BIO’s onsite meeting space in San Francisco, tips and tricks for using the system, and how to schedule your meetings with different location options. Also, get a look at how you can stay in-the-know about networking and other opportunities during JPM Week. For more information about BIO Partnering at JPM Week, please visit: https://www.bio.org/events/bio-partnering-jpm/registration   

This webinar covers:  

• Preview of BIO’s onsite meeting space in San Francisco
• Partnering best practices & how to schedule your meetings 
• Live demo of the partnering system & advanced features
• Intro to BIO and Novateur Ventures’ JPM Week Events Guide mobile app
• Q&A with the host

So far, 2024 biotech markets and funding are trending better than last year, but volatility is on the upswing. Join this webinar to hear experienced perspectives on what investment signals to be watching to position yourself for a strong springboard into closing out the year before JPM Week restarts the cycle. This webinar will also preview the panel topics and speakers for the upcoming BIO Investor Forum as well as demonstrate how best to utilize the event’s BIO One-on-One Partnering System to connect with investors and more.

The FDA has established the Split Real-Time Application Review (STAR) pilot program. The purpose of this program is to shorten the time from the date of a complete submission to the action date, in allowing earlier patient access to therapies that address an unmet medical need.

In this webinar, FDA staff will give an overview of the program, including the eligibility criteria for the pilot, and will answer your questions about participating in the program.

View this conversation highlighting how BIO member companies are leveraging biotechnology innovations to enable advances in climate adaptation, mitigation, and resilience. Hear how diverse feedstocks and manufacturing processes are targeting emission reduction breakthroughs in hard-to-reach sectors. Learn how regulation and policy can better incentivize innovation and be structured to support new and emerging technologies throughout research, development, demonstration, and deployment.

Following reauthorization by Congress of the SBIR/STTR Programs in 2022, there are new rules companies should familiarize themselves with concerning required disclosures of foreign affiliations or relationships with foreign countries. In addition to mandating disclosures prior to receiving SBIR awards, companies must also regularly update NIH following any changes to a disclosure. View this webinar organized by the Biotechnology Innovation Organization (BIO) for a comprehensive discussion on how to effectively navigate these new rules as you apply for SBIR awards.

This webinar is co-hosted by the National Institutes of Health (NIH) Seed Office.

With the majority of biological studies conducted in academic settings but nearly all innovative new drug clinical trials sponsored by industry, improving translational research success rates for commercialization is critical to bringing new treatments to patients. Surveys of academic tech transfer offices and the biopharma industry executives working on such alliances cite as obstacles two highly controllable factors: disagreement about alliance performance metrics and misalignment of deal terms priorities. This panel discusses best practices for removing such obstacles to accelerate more promising ideas into clinical development for patients.

BIO's updated 2023 report, "U.S. Biotechnology Translational Research: Partnership Models, Management Principles, and Best Practices," is available for download at the link below.  The webinar also summarizes major findings from that BIO report as context for the panel discussion and audience Q&A.

The Cell and Gene Therapy (CGT) Science Series is a quarterly seminar series focused on scientific topics related to cell and gene therapy products. The CGT Science Series is intended to foster scientific exchange between the Biotechnology Innovation Organization (BIO), the American Society of Cell & Gene Therapy (ASGCT), and Center for Biologics Evaluation and Research (CBER) review staff on a variety of topics that span the CGT product lifecycle. The seminars are planned as 60-minute virtual webinars featuring a speaker from one of the three organizations. The CGT Science Series will enable a deep dive into a specific technical and/or scientific area. Topics in the series may include but are not limited to, nonclinical, CMC, clinical, or post-market phases of development related to CGT product lifecycle.

Moderator:
– Anne-Virginie Eggimann, Tessera

Opening Remarks:
– Cartier Esham, Senior Advisor, Biotechnology Innovation Organization (BIO)

Speaker:
– Jing Liao, Director, Vector Development and Operations, Alexion Pharmaceuticals

This Biotechnology Innovation Organization (BIO) webinar explains that the days of the one-page marketing slicks are over, as companies and investors now expect brief “Pitch Decks” when engaging in conversations with them. This diverse panel of experts explain how to make an effective pitch to them, so that you can tailor your BIO partnering strategy to achieve a maximum ROI.

During this webinar, panelists discuss strategies for biotechnology companies to manage economic downturns and weakened investor interest in the biotech industry. Our expert panel of industry leaders share their insights and experiences on how to maintain momentum and emerge stronger during periods of economic uncertainty.

This webinar is designed to provide practical advice and actionable strategies that can be implemented immediately. The panel covers the following topics:

• Effective communication and investor relations strategies during economic downturns

• Actions biotechs can take to cut costs without sacrificing innovation and growth

• How to pitch to investors during weakened investor interest periods

U.S. Department of Justice (DOJ) statistics suggest that enforcement will be a top government priority in 2023, including for pharma/life sciences. Warning or untitled letters from the U.S. Food and Drug Administration (FDA) will serve as ammunition for DOJ cases. Statements about product safety will be heavily scrutinized.

Do you know what to watch out for? Has your company trained its employees and marketing agencies on how to appropriately implement the requirements for promotion? What activities require extra vigilance? The prior downturn in enforcement can be linked to the development of a response to COVID-19, which diverted government resources across the board. Now trends suggest the FDA, DOJ, and Office of Inspector General (OIG) will return to active healthcare enforcement in 2023 for violations of the Food Drug and Cosmetic Act (FDCA), False Claims Act and the Anti-Kickback Statute in part attributable to the goal of obtaining additional financial recoveries.

This webinar hosted by the Biotechnology Innovation Organization (BIO) has these learning objectives:
—Understand the current trends for government enforcement
—Dissect the compliance implications of increased enforcement on the industry
—Identify specific cases that are clear examples for company concern
—Isolate the key principles for avoiding violations

ON-DEMAND
COMMUNICATIONS COMPLIANCE COURSES
FOR PROFESSIONAL DEVELOPMENT

Special Discount
Buy 2 course registrations, Get 1 FREE
through May 15, 2023
in honor of this webinar!

The Center for Communication Compliance (CCC) helps biopharmaceutical companies achieve efficient, compliant innovation in a digital world through its proprietary on-demand business solutions in education, technology, and change management.

The CCC eLearning System has set an unmatched standard for confirming regulatory competency through engaging mastery tests and expert education content across more than a dozen course options.

SEE COURSES LIST